| 2,401 | 3 | 86 |
| 下载次数 | 被引频次 | 阅读次数 |
目的:对连花清瘟联合常规疗法治疗新型冠状病毒肺炎的随机对照试验进行系统评价，旨在探求连花清瘟联合常规疗法治疗新型冠状病毒肺炎的临床证据。方法:检索常用的数据库知网、CBM、万方、VIP、PubMed、Embase、Cochrane Library中有关连花清瘟联合常规疗法治疗新型冠状病毒肺炎的随机对照试验。对符合纳入标准的文献使用Revman5.4进行系统评价，并使用GRADE系统进行证据等级评价，以期得到临床证据。结果:最终纳入13篇文献，结果显示连花清瘟联合常规疗法在总有效率、症状改善率、症状消失时间、发热消失时间、住院时间、CT好转率、转重型率方面优于常规疗法，且不良反应较少，安全性优于常规疗法，结果具有统计学意义。结论:连花清瘟联合常规疗法治疗新型冠状病毒肺炎的疗效和安全性较好，但还需要更多的临床试验证据。
Abstract：Objective:To systematically review the randomized controlled trials(RCTs) of Lianhua Qingwen combined with conventional therapies in the treatment of Coronavirus Disease 2019(COVID-19) to explore the clinical evidence of this therapeutic protocol. Methods:The commonly-used databases, such as CNKI,CBM,Wanfang Data, VIP,PubMed, Embase, and Cochrane Library, were searched for RCTs of Lianhua Qingwen combined with conventional therapies in the treatment of COVID-19. The research articles meeting the inclusion criteria were systematically reviewed using RevMan5.4,and the GRADE system was used to evaluate the level of evidence in order to obtain clinical evidence. Results:Thirteen research articles were finally included, and the results showed that Lianhua Qingwen combined with conventional therapies was superior to conventional therapies alone in terms of total effective rate, symptom improvement rate, symptom disappearance time, fever disappearance time, hospitalization time, CT improvement rate, and conversion rate. This therapeutic protocol of combination resulted in fewer adverse reactions and was safer than conventional therapies alone. The results were statistically significant. Conclusion:The efficacy and safety of Lianhua Qingwen combined with conventional therapies against COVID-19 are good, but more clinical evidence is needed.
[1]Chen Y,Liu Q,Guo D.Emerging coronaviruses:Genome structure,replication,and pathogenesis[J].J Med Virol,2020,92(4):418-423.
[2]李六亿，吴安华.新型冠状病毒医院感染防控常见困惑探讨[J].中国感染控制杂志，2020,19(2):1-4.
[3]Callaway E,Cyranoski D.China coronavirus:Six questions scientists are asking[J].Nature,2020,577(7792):605-607.
[4]Grein J,Ohmagari N,Shin D,et al.Compassionate use ofremdesivir for patients with severe Covid-19[J].N Engl J Med,2020,382:2327-2336.
[5]Spinner C D,Gottlieb R L,Criner G J,et al.Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19:A randomized clinicaltrial[J].JAMA,2020,324:1048-1057.
[6]国家卫生健康委办公厅，国家中医药管理局办公室.新型冠状病毒感染的肺炎诊疗方案(试行第五版)[EB/OL].[2020-02-05].http://www.nhc.gov.cn/www.nhc.gov.cn/yzygj/s7653p/202002/ 3b09b894ac9b4204a79db5b8912d4440.shtmL.
[7]吴以岭.气络论[M].北京：科学技术文献出版社，2018:1327-1329.
[8]杨猛，杨少华，杨眉，游顶云.中药连花清瘟治疗新型冠状病毒肺炎的系统评价[J].中国药物评价，2020,37(2):126-130.
[9]Wang S H,Liu J F,Zhang Y L,et al.Systematic review of efficacy and safety of Lianhua Qingwen Capsules intreatment of viral influenza[J].China J Chin Mater Med,2019,44(7):113-117.
[10]Moher D,Liberati A,Tetzlaff J,Altman,D.G.,& PRISMA Group (2009).Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement[J].PLoS medicine,6(7),e1000097.
[11]Claudia M P,Mario G C.GRADE system,systematic and transparent evaluation.Reumatol Clin,2018,14(2) :65.
[12]程德忠，王文菊，李毅，等.51例新型冠状病毒肺炎患者应用中药连花清瘟疗效分析：多中心回顾性研究[J].天津中医药，2020,37(5):509-516.
[13]柳丽丽，袁连方，冯毅，等.阿比多尔联合连花清瘟胶囊治疗新型冠状病毒肺炎的临床观察[J].广东医学，2020,41(12):1207-1210.
[14]孙惠敏，徐锋，张玲，等.连花清咳颗粒治疗轻型、普通型新型冠状病毒肺炎临床疗效观察[J].中国实验方剂学杂志，2020,26(14):29-34.
[15]汪升早，王华军，陈鸿明，等.连花清瘟胶囊和α-干扰素联合洛匹那韦/利托那韦治疗新型冠状病毒肺炎30例[J].蚌埠医学院学报，2020,45(2):154-155.
[16]余平，李叶子，万少兵，等.连花清瘟颗粒联合阿比多尔治疗轻度新型冠状病毒肺炎的疗效观察[J].中国药学杂志，2020,55(12):1042-1045.
[17]芳菲，杨磊，秦守成，等.连花清瘟颗粒治疗儿童新型冠状病毒肺炎疑似病例42例[J].中国新药杂志，2020,29(24):2809-2812.
[18]时佳，杨宗国，叶晨，等.中西医结合治疗上海地区49例非危重型新型冠状病毒肺炎临床疗效观察[J].上海中医药杂志，2020,54(4):30-35.
[19]姚开涛，刘明瑜，李欣，等.中药连花清瘟治疗新型冠状病毒肺炎的回顾性临床分析[J].中国实验方剂学杂志，2020,26(11):8-12.
[20]吕睿冰，王文菊，李欣.连花清瘟颗粒联合西药常规疗法治疗新型冠状病毒肺炎疑似病例63例临床观察[J].中医杂志，2020,61(8):655-659.
[21]夏文广，安长青，郑婵娟，等.中西医结合治疗新型冠状病毒肺炎34例临床研究[J].中医杂志，2020,61(5):375-382.
[22]田咏，马兆润，毕颖斐，等.基于连花清瘟胶囊中西医结合治疗早期新型冠状病毒肺炎的临床研究[J].天津中医药，2021,38(10):1236-1240.
[23]谭杜勋，石文磊，刘楠，等.连花清瘟胶囊在新冠肺炎中早期抗病毒、抗炎的疗效观察[J].中国处方药，2021,19(5):92-93.
[24]陈超武，李晓良，刘亚峰，等.连花清瘟胶囊治疗新型冠状病毒肺炎临床研究[J].中西医结合研究，2021,13(1):1-4.
[25]Liu X F,Guo D Z,Yang Q,et al.Prevention and treatment of corona virus disease 2019 based on turbid toxin theory[J].Chinese Critical Care Medicine,2020,32(1):8-9.
[26]刘清泉，夏文广，安长青，等.中西医结合治疗新型冠状病毒肺炎作用的思考[J].中医杂志，2020,61(06):463-464.
[27]Suns J,Lian G T,Lu Y et al.Study on the effects of Langchuangqing Granule on system iclupusery themato sushin animal[J].Chin J Chin Pharmacol,2016,32(12):1125-1128.
[28]Kiyohara H,Ichino C,Kawamura Y,et al.Patchouli alcohol:In vitro direct anti-inluenza virus sesquiterpene in Pogostemon cablin Benth[J].J Nat Med,2012,66(1):55-61.
[29]Dong L,Xia J W,Gong Y,et al.Efect of Lianhuaqingwen capsules on airway inlammation in patients with acute exacerbation of chronic obstructive pulmonary disease[J].Evid-Based Compl Alter Med,2014:637969.
[30]Ding Y W,Zeng L J,Li R F,et al.The Chinese prescription lianhua qingwen capsule exerts anti-influenza activity through the inhibition of viral propagation and impacts immune function[J].BMC Compl Altern Med,2017,17(1):130.
[31]凌晓颖，陶嘉磊，孙逊，等.基于网络药理学的连花清瘟方抗冠状病毒的物质基础及机制探讨[J].中草药，2020,51(7):1723-1730.
[32]王林，杨志华，张浩然，等.连花清瘟治疗新型冠状病毒(2019-nCoV)肺炎网络药理学研究与初证[J].中药材，2020,43(3):772-777.
基本信息:
DOI：10.13412/j.cnki.zyyl.20220419.002
中图分类号:R259
引用信息:
[1]王诗恒,秦培洁,张凤霞,等.连花清瘟联合常规疗法治疗新型冠状病毒肺炎的随机对照试验的系统评价[J].中药药理与临床,2022,38(06):175-180.DOI:10.13412/j.cnki.zyyl.20220419.002.
基金信息:
基础研究重大项目前期研究专项(编号：2019YFC1708402)
2022-04-20
2022-04-20
2022-04-20